Mechanism of Action
Rabeprazole suppresses gastric acid secretion1 while domperidone increases esophageal peristalsis and speeds gastric emptying2 providing dual symptom relief.
Uses Under medical guidance, Perbloc-DSR can effectively treat:
- Frequent heartburn and GERD
- Ulcers caused by excess stomach acid
- Nausea, bloating and appetite loss
- Conditions requiring sustained acid reduction
Benefits
Potential advantages of the rabeprazole-domperidone mix include:
- Powerful acid suppression for healing damaged tissue
- Preventing vomiting and nausea triggered by PPI use
- Enabling patients to complete PPI-based triple therapy
- Restoring nutritional intake impaired by upper GI issues
Dosage
The standard Perbloc-DSR dose is 1 tablet daily 30 minutes before food, or as directed by your physician. Strictly follow guidance on usage.
Warning Signs
Inform your doctor promptly if unusual fatigue, muscle cramps, sudden weight loss or severe abdominal pain occurs when on Perbloc-DSR.
Side Effects and Precautions Like all medications, Perbloc-DSR can cause side effects. Common side effects include diarrhea, headache, dizziness, flatulence, weakness, nausea, vomiting, constipation, abdominal pain, insomnia, cough, inflammation of the nose, and pharyngitis1. It’s important to consult with your healthcare provider if you experience any of these symptoms12.Product Image Gallery
Customer questions & answers
-
I usually experience weakness and stomach pain s when taking this medicine.
-
Q I usually experience weakness and stomach pain s when taking this medicine. answer nowAsked by Godspower Omarejivwie on October 26, 2024 8:30 amA
Hi Godspower,
I'm sorry to hear about the discomfort you're experiencing. Weakness and stomach pain can sometimes occur with Perbloc-DSR. To help reduce these effects, try taking it with food, as this may ease stomach-related symptoms. However, if the pain and weakness persist or worsen, it’s best to consult your doctor, as they may adjust your dose or suggest an alternative.
Reviews
There are no reviews yet.